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Abbreviations 1 
ACTH, adrenal corticotrophin-releasing hormone 2 
BL, baseline 3 
CI, confidence interval  4 
CRPC, castration-resistant prostate cancer 5 
D, Dexamethasone 6 
ECOG, Eastern Cooperative Oncology Group 7 
HPA, hypothalamic-pituary axis 8 
IQ, interquartile  9 
MDSC, myeloid-derived suppressor cell 10 
MVA, multivariate analysis 11 
NLR, neutrophil-to-lymphocyte ratio 12 
P, Prednisolone 13 
PSA, prostate-specific antigen 14 
Treg, regulatory T-cell 15 
UVA, univariate analysis 16 
Wk(s), week(s) 17 
18 
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MicroAbstract 1 
Concerns exist that low-dose corticosteroids may adversely affect outcome in patients with 2 
castration-resistant prostate cancer (CRPC), due to its tumour-promoting and immunosuppressive 3 
characteristics. An increased neutrophil-lymphocyte ratio (NLR), an indirect measure of tumour- 4 
inflammation, associated with a shorter PSA progression-free interval and a shorter overall survival, 5 
in 75 treatment-naïve CRPC patients treated with low-dose corticosteroids in a prospective clinical 6 
trial. 7 
 8 
Clinical Practice Points 9 
Corticosteroids enjoy widespread use in patients with castration-resistant prostate cancer (CRPC). 10 
Mounting concerns have arisen that corticosteroids fuel tumour growth by promiscuous activation of 11 
the androgen receptor (AR) and through glucocorticoid receptor (GR) signalling, leading to AR- 12 
independent CRPC progression and an array of immunosuppressive effects. These include inhibition 13 
of leukocyte trafficking, apoptosis of immature T-cells, polarisation of T-cells into cells with a 14 
regulatory phenotype, and accumulation of myeloid-derived suppressor cells and tolerogenic 15 
dendritic cells. Corticosteroids may adversely impact outcome in mCRPC patients supported by data 16 
from the COU-AA-301, AFFIRM, and TROPIC trials. In addition, steroid withdrawal has been linked to 17 
biochemical responses. NLR, a ratio of systemic neutrophil-lymphocyte levels, has been proposed as 18 
a biomarker of a cancer-promoting systemic inflammation, and is now a well established biomarker 19 
of poor prognosis. Previous reports suggested corticosteroid therapy itself may induce NLR rises, 20 
which indeed was the case, however the timing and extent strongly varied between patients. Our 21 
findings indicate that treatment-naïve CRPC patients with a high baseline NLR, treated with low-dose 22 
corticosteroids, show a more rapid biochemical progression and have a shorter overall survival, than 23 
those with low baseline values. Those patients showing a strong and rapid increase in NLR during the 24 
first 6 weeks had a shorter benefit and lower odds of biochemical respons, suggesting corticosteroids 25 
or an induced systemic inflammatory response may adversely affect outcome. Whether 26 
corticosteroids unequivocally drive prostate cancer progression in patiens with high NLR tumours has 27 
not been demonstrated, as the trial lacked a control arm. Our results nevertheless implicate 28 
potentially adverse effects of low-dose corticosteroids; we particulary advocate caution in the use of 29 
therapeutic or palliative low-dose corticosteroids in patients with a high NLR and recommend 30 
discontinuation of supportive corticosteroid regimens following tumour progression.  31 
 32 
33 
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Abstract 1 
Objective: The neutrophil-lymphocyte ratio (NLR) is highly prognostic across many tumour types, 2 
predictive of treatment outcome in advanced prostate cancer (PCa), and a indirect measure of 3 
tumour-associated inflammation. We evaluated the impact of low-dose steroids on NLR in 4 
castration-resistant PCa (CRPC). 5 
Patients and methods: The NLR was evaluated in a prospective phase II RCT comparing daily 6 
prednisolone 10mg and dexamethasone 0.5mg administered to 75 chemotherapy and 7 
abiraterone/enzalutamide-naïve CRPC patients. NLR was examined at baseline (BL), after 6- and 12- 8 
weeks of corticosteroid treatment; associations with >50%PSA response, time to PSA progression; 9 
TTPSAPD) and OS were tested using regression analyses.  10 
Results: The median NLR for all evaluable patients was 2.6 at BL; 2.9 at 6-wks; and 4.0 at 12-wks. 11 
Following low-dose corticosteroid, 46 patients had a decline in PSA with 24 confirmed responders. BL- 12 
NLR(log10) associated with PSA response (OR=34.6;95%CI=2.0-589.1;P=0.014), and with extent of PSA 13 
decline (P=0.009). A favourable BL-NLR (<median) associated with 5.5- higher odds of  PSA>50% 14 
response (95%CI=1.3-23.9;P=0.02). Higher BL-NLR(log10) associated with TTPSAPD 15 
(HR=9.5;95%CI=2.3-39.9;P=0.002). In MVA BL-NLR associated with TTPSAPD (HR=3.5;95%CI=1.5- 16 
8.1;P=0.003). NLR at 6-weeks associated with duration of benefit; in the favourable NLR category 17 
TTPSAPD was 10.8mo, converters to unfavourable (>median) category 4.5mo, those remaining in a 18 
unfavourable category 1.5mo (95%CI=0.5-2.5;P=0.003). OS was 33.1mo (95%CI=24.2-42.0) and 19 
21.9mo (95%CI=19.3-24.4) for those with favourable and unfavourable BL-NLR, respectively. 20 
Conclusion: Treatment-naïve CRPC patients with high-BL or on-treatment NLR appear not to benefit 21 
from low-dose corticosteroids. The immunological implications of unfavourable NLR, and whether 22 
corticosteroids drive PCa progression in patients harbouring high-NLR warrant further study. 23 
24 
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Introduction 1 
Corticosteroids are widely used in the management of patients with metastatic castration-resistant 2 
prostate cancer (mCRPC)(1). Incontrovertible evidence exists that corticosteroids suppress the 3 
adrenocorticotrophic hormone (ACTH) axis, thereby decreasing levels of the peripheral adrenal 4 
androgens dihydrotestosterone and testosterone(2). Even though corticosteroids induce PSA 5 
responses(3), circulating tumour cell (CTC) falls(4) and objective responses(5,6), prolonged use 6 
suggests no survival advantage in the CRPC state. Concerns are also emerging that the widespread 7 
and sustained use of these agents in mCRPC may not be beneficial to all, due to pleiotropic effects on 8 
multiple signalling pathways impacting tumor-promoting inflammation, as well as promoting an 9 
immunosuppressive environment(6–9). 10 
Corticosteroid alter cellular differentiation programs that result in the accumulation of regulatory T- 11 
cells (Tregs) and myeloid-derived suppressor cells (MDSC)(11,12), known to drive tumour growth and 12 
affect outcome(13–15). Corticosteroids may additionally decrease peripheral lymphocyte and 13 
increase granulocyte counts, increasing the NLR(8). A high NLR has been reported to represent an 14 
adverse prognostic factor in over 40,000 cancer patients with different tumor types(16). In patients 15 
with mCRPC, a high baseline (BL) NLR also is associated with a lower rate of response to 16 
abiraterone(17), enzalutamide(18) and cabazitaxel chemotherapy(19). BL-NLR and on-treatment NLR 17 
have not been studied in relation to response, duration of response and survival in CRPC patients 18 
treated with low-dose corticosteroids.  19 
We hypothesized that a high NLR reflects an immune contexture that promotes tumour growth 20 
through: (I) the secretion of cytokines by inflammatory cells recruited to the tumour 21 
microenvironment, (II) reduced immune-surveillance due to the generation and expansion of myeloid- 22 
derived suppressor cells, regulatory T-cells (Tregs) and suppression of cytotoxic T-lymphocytes, and 23 
(III) senescence evasion and metastases promotion through direct and indirect actions of MDSCs. 24 
These concepts are substantiated by a good correlation between peripheral blood MDSC levels and 25 
NLR (20,21).  26 
Studies on the impact of corticosteroids on the anti-prostate cancer immune response are therefore 27 
warranted. This led us to evaluate the impact of low-dose corticosteroids on the NLR in treatment- 28 
naïve CRPC patients treated on a prospective investigator-initiated randomized phase II trial 29 
(Prednisolone or Dexamethasone, POD trial) comparing low dose prednisolone 5mg twice-daily versus 30 
low dose dexamethasone at 0.5mg once-daily versus intermittent high-dose dexamethasone at 8mg 31 
for three days on a 3 week schedule(3). As corticosteroids increase the NLR, we hypothesized that 32 
patients with a high BL or on-treatment NLR, indicative of a high intratumoral and systemic 33 
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inflammatory state, would have a shorter PSA progression-free interval and a shorter time of benefit, 1 
compared to those with a low NLR. Corticosteroids are frequently used as supportive treatment in the 2 
latter stages of the disease where a high NLR is commonly seen; therefore it is of clinical significance 3 
to medical oncologists to ascertain whether NLR assessments may be utilized to select for patients 4 
that may have benefit or even have detriment from corticosteroid therapy, due to an induced increase 5 
in tumor-promoting inflammation driving prostate cancer growth(18).  6 
 7 
8 
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Methods 1 
Patients 2 
All patients and healthy volunteers provided written informed consent prior to blood sampling. The 3 
local National Health Service research ethics committee approved the initial protocol on the single- 4 
centre, randomised, open-label, phase 2 trial of daily prednisolone versus daily dexamethasone versus 5 
intermittent dexamethasone in patients with CRPC (POD trial)(3). We conducted an unplanned 6 
retrospective analysis to study BL-NLR and NLR changes following the initiation of corticosteroid 7 
treatment in the POD trial. The inclusion and exclusion criteria are reported in the original publication, 8 
and comprise patients with CRPC (defined as having testosterone levels <2 nmol/l on androgen 9 
deprivation therapy or following bilateral orchidectomy) and progressive disease (PSA progression 10 
using three serum PSA measurements at least 7 days apart). In brief, patients were randomised in a 11 
1:1:1 ratio among intermittent oral dexamethasone (8 mg twice daily for 3 days every 3 weeks), daily 12 
oral dexamethasone (0.5 mg once-daily), and oral prednisolone (5 mg twice-daily), until biochemical 13 
progression or unacceptable toxicity. Randomisation to the intermittent dexamethasone arm was 14 
stopped early because of lack of antitumor activity, and the analyses in this manuscript are restricted 15 
to the 75 patients randomised to the other two arms of the trial. Patient BL investigations included 16 
medical history, physical examination, Eastern Cooperative Oncology Group (ECOG) performance 17 
status, serum PSA (within 7 days of randomisation), serum testosterone, and routine haematology 18 
and biochemistry tests. The NLR was defined as the quotient of absolute peripheral neutrophil count 19 
(cells/mm3) by absolute peripheral baseline lymphocyte count (cells/mm3). The neutrophil and 20 
lymphocyte counts were collected from the electronic patient record. In the POD trial haematological 21 
assessments were used from time of screening to the first day of treatment. All assessments in the 22 
POD trial were performed at 6-week intervals, and included physical examination, serum PSA, 23 
haematological and biochemistry testing. The primary endpoint was PSA response, defined as the first 24 
timepoint with a 50% decline in serum PSA which is confirmed more than 4 weeks later, and secondary 25 
endpoints included time to PSA progression. In PSA nonresponders, progression was defined as a 25% 26 
increase over the nadir value (provided the rise was a minimum of 5 ng/ml) and confirmed by a second 27 
value at least 1 wk later. In PSA responders, progression was defined as a 50% increase over the nadir 28 
value (provided the rise was a minimum of 5 ng/ml) and confirmed by a second value at least 1 wk 29 
later. Patient survival was updated to 1 February 2015. 30 
Statistical considerations 31 
All results are presented as the median with interquartile (IQ) ranges for continuous variables. For 32 
non-normally distributed data, the Spearman rank-order correlation (r) was used to test for 33 
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associations, the Mann-Whitney test was used to test for differences between two groups, and the 1 
Wilcoxon signed-rank test was used for paired samples with repeated measurements following 2 
treatment. Lactate dehydrogenase (LDH), baseline PSA, alkaline phosphatase (ALP) and NLR were log10 3 
transformed prior to testing in regression analysis. The relationship between continuous and 4 
dichotomized variables (at the median) and response were analysed using logistic regression models, 5 
with linear univariate regression model testing the relationship between BL-NLR and extent of PSA 6 
decline. Prognostic factirs tested in univariate analyses included metastatic disease, ECOG 7 
performance status, baseline PSA, categorised baseline testosterone, lactate dehydrogenase, 8 
haemoglobin, albumin, alkaline phosphatase and trial randomisation arm. All variables with a P<0.10 9 
in UVA were selected for further testing in multivariate (MVA) regression analysis. Median OS and 10 
progression-free survival (PFS) were estimated using the Kaplan-Meier method with comparison 11 
between groups using the log-rank test. Additionally survival analyses were performed at the 6 and 12 
12-week landmarks as previously reported(22). Boxplots where depicted using the Tukey method for 13 
plotting the whiskers and outliers. A Bonferroni correction was applied for multiple testing at BL, week 14 
6 and week 12. All P values <0.05 were considered significant (and <0.025 or <0.017 with Bonferroni 15 
correction, for 2 or 3 time points tested). SPSS Statistics for Macintosh, Version 22.0 (IBM Corp, 16 
Armonk, NY) and GraphPad Prism version 6.0 for Macintosh (GraphPad Software, La Jolla, California) 17 
were used for the statistical analyses and figures. 18 
 19 
20 
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Results 1 
NLR following the initiation of low dose corticosteroids 2 
We evaluated BL-NLR and the change in NLR after initiation of continuous low-dose corticosteroid 3 
treatment on this trial. The median NLR for all evaluable patients was 2.6 at BL; 2.9 at 6-weeks; and 4 
4.0 at 12-weeks (Supplementary table S1), with no significant differences between the two 5 
randomization arms at BL. When testing paired samples following corticosteroid treatment initiation 6 
the increase observed from BL to week-6 and weeks-12 was statistically significant (Wilcoxon paired 7 
rank-test, n=50, P<0.001 and n=48, P<0.001, respectively). In the prednisolone arm the NLR increased 8 
from a BL of 2.6 (IQ range of 2.0-3.4) to 3.7 at 6-weeks (IQ range of 2.8-5.9) to 4.1 at 12-weeks (IQ 9 
range of 2.8-7.2). In the dexamethasone arm the NLR increased by a lesser extent from a BL of 2.6 (IQ 10 
range of 2.0-3.5) to 2.7 at 6-weeks (IQ range of 1.9-4.0) and 4.0 at 12-weeks (IQ range˙ of 2.0-5.4). 11 
There was a significantly lower NLR at week-6 for the patients on dexamethasone (P=0.02). The 12 
median granulocyte counts at BL, 6- and 12-weeks were 4.0 (IQ range 3.4-5.1, n=69), 5.4 (IQ range 4.1- 13 
6.8, n=55), and 5.7x109 cells (IQ range 4.5-7.2, n=51), respectively. The median lymphocyte counts 14 
were 1.5  (IQ range 1.2-1.9, n=70), 1.7 (IQ range 1.2-2.1, n=56) and 1.5 x109 cells (IQ range 1.2-1.8, 15 
n=51), respectively (Figure 1). The increased NLR was due to an increase in granulocytes at the 6- and 16 
the 12-week time point (in 42 out of 50, and in 41 out of 48 patients, respectively; both with P<0.01), 17 
without any statistically significant overall decrease in lymphocyte counts (P=0.09 and p=0.20, 18 
respectively). 19 
Baseline NLR and response to corticosteroids 20 
Of the evaluable 73 patients, 46 patients had a decline in PSA from BL following corticosteroid 21 
treatment initiation, with a confirmed PSA>50% response in 24 patients. No responses were witnessed 22 
in the arm with intermittent oral dexamethasone (8 mg twice daily for 3 days every 3 weeks), 23 
suggesting an anti-tumour activity of daily single-agent low-dose corticosteroids. Relationships 24 
between NLR and response could be evaluated in 69 (94.5%) patients with a documented BL-NLR. In 25 
univariate logistic regression analyses, BL-NLR associated with a PSA>50% response (odds ratio=34.6, 26 
95% confidence interval [CI]=2.0-589.1, P=0.014), and with the extent of PSA decline in those patients 27 
that responded (P=0.009). A favourable BL-NLR (<2.6 or median) associated with a 5.5-fold higher odds 28 
of a PSA>50% response than those in the unfavourable (≥2.6 or median) BL-NLR category (95%CI=1.9- 29 
15.8; P=0.001, n=69). At the 6-week time point, 50 (72.5%) patients were evaluable with both a 30 
documented BL and 6-week NLR. In 68% of evaluable patients the NLR remained unchanged (30.0% 31 
remained NLR<median; 38.0% remained NLR≥median), however there were some conversions from 32 
low to high (28.0%), and from high to low (4.0%). Patients remaining in the favourable NLR category 33 
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at 6-weeks showed a 10.3-fold higher odds of a PSA>50% response compared to those that remained 1 
in the unfavourable category (95%CI=2.1-50.5; P=0.002, n=34). Patients that converted from a 2 
favourable to a unfavourable NLR showed a trend for a decreased response rate (P=0.086, n=16). 3 
Furthermore, the PSA progression-free interval was longer in patients with a low BL-NLR; as a 4 
continuous variable BL-NLR associated with the duration of PSA response (95%CI 2.3-39.9, P=0.002). 5 
Patients with a BL-NLR<median had a PSA progression-free interval of 6.1 months (95%CI 5.3-7.0), 6 
while patients with a BL-NLR≥median had a median interval of 3.3 months (95%CI 2.8-4.2, difference 7 
in median PFS of P=0.003; Figure 2A. These results indicate that a higher BL-NLR associates with 8 
reduced CS antitumour activity and a shorter duration of response.  9 
After 6 weeks of treatment, patients that remained in the favourable NLR category were more likely 10 
to benefit from low-dose corticosteroids than those in the unfavourable category. Even though 6 11 
patients that converted to an unfavourable NLR category still showed a PSA>50% response, the 12 
duration of responses were brief. The median time to PSA progression for those in the favourable NLR 13 
category was 8.5 months (95% CI 5.2-14.8), those converting to unfavourable category 4.5 (95% CI 14 
2.8-6.2) and those remaining in a unfavorable category only 1.5 months (95% CI 0.5-2.5; P=0.003; 15 
results for favourable and unfavourable NLR shown in Figure 2B). Univariate and multivariate analyses 16 
(MVA) are shown in Table 1. In MVA BL-NLR was independently associated with the PSA progression- 17 
free interval (hazard Ratio [HR] 3.5; 95% CI 1.5-8.1, p=0.003). Prognostic factors that retained 18 
significance in multivariate testing were BL-PSA and randomization arm (D versus P), with a borderline 19 
significance for BL-testosterone.   20 
Baseline NLR and overall survival. 21 
The median overall survival (OS) of all 75 evaluable patients was 25.6 months (95% CI 14.9-42.0), with 22 
no significant difference between the two steroid regimens (P=0.15). As a continuous variable BL-NLR 23 
was significantly associated with OS (HR 5.5 with 95%CI of 1.3-24.0, P=0.024); patients in the 24 
favourable NLR category showed median OS estimates of 33.1 months (95% CI 24.2-42.0), and 21.9 25 
months (95% CI 19.3-24.4) for patients with an unfavourable NLR (P=0.006; Figure 3). On-treatment 26 
NLR was not prognostic for OS at 6-weeks (HR 1.7 with 95%CI of 0.6-5.2) and not prognostic at 12- 27 
weeks (HR 2.2 with 95%CI of 0.6-8.3). In MVA, only ECOG≥2, LDH and haemoglobin retained 28 
significance, with borderline significance for BL-NLR (HR 2.0 with 95%CI of 1.0-4.0, P=0.062; 29 
Supplementary Table S2).  30 
31 
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Discussion 1 
Parallel to an increasing insight into the molecular mechanisms of glucocorticoid’s anti-inflammatory 2 
effects(7), mounting concerns have arisen regarding the prolonged use of corticosteroids in mCRPC 3 
(9). Corticosteroids have an array of effects that dampen the inflammatory response by creating a 4 
immune-suppressive environment that may support tumor growth through the evasion of immune 5 
surveillance(23).  These include inhibition of leukocyte trafficking and multiple effects on the degree 6 
of adaptive immunity by altering cellular differentiation programs(8).  Studies on the impact of 7 
therapeutic and supportive corticosteroid treatment on the immune response in prostate cancer 8 
patients are therefore now urgently required.  9 
 10 
We identified a strong relation between NLR in chemotherapy/ abiraterone/ enzalutamide-naïve 11 
patients and benefit from low-dose corticosteroid therapy, suggesting little or no benefit from 12 
single-agent corticosteroids in patients with high NLR. These results indicate that steroids simply 13 
may be insufficient as a therapeutic option in those patients with a high NLR, or may even suggest 14 
that in patients with a cancer-induced systemic inflammatory response, corticosteroid treatment 15 
may even be detrimental.  16 
 17 
Most of the immunosuppressive and anti-inflammatory actions of corticosteroids are directly or 18 
indirectly attributable to transcriptional effects on GR. GR signaling induces apoptosis in immature 19 
double-positive CD4+ CD8+ T-cell in the thymus(24);  monocytic precursors are also blocked in their 20 
pathway of maturation and cells with an anti-inflammatory MDSC phenotype accumulate(11,12,25);  21 
dendritic cell (DC) maturation is also suppressed and turn into tolerogenic semi-mature DCs(26) that 22 
polarize T-cell differentiation towards a regulatory T-cell profile (Tregs (25,27)).  These 23 
immunomodulatory cells shape the tumor microenvironment by creating an immune-suppressive 24 
milieu interieur that impairs functional effector T and natural killer (NK) cell function.  25 
Corticosteroids also directly reduce T-cell functionality by numerous mechanisms, including 26 
enhancing PD-1 expression(28) and repressing transcription of pro-inflammatory cytokines (e.g. IL-2, 27 
IFN-γ and TNF- α) and chemokines that decrease migration and survival. Our results indicate that a 28 
high NLR rise is mainly caused by a corticosteroids-induced neutrophilia, of which cancer-associated 29 
neutrophils are known to support cancer growth. Recent immunophenotyping data from a 30 
prospective cohort of mCRPC patients indicates a positive correlation between NLR and peripheral 31 
blolod MDSC levels in patients on long-term corticosteroid treatment(21,29).  In addition to an 32 
association between NLR and circulating MDSCs, significantly higher tumour-infiltrating MDSCs were 33 
detected in CRPC biopsies of patients with high versus low NLR(30). This in part may explain the 34 
12 NLR in PoD trial  
 
 11/08/17 
 
impact of BL- corticosteroid treatment on outcome in mCRPC patients, with inferior OS in patients 1 
with a higher NLR  in the COU-AA-301, AFFIRM and TROPIC trials (31–33). In addition to these 2 
immunomodulatory effects, adverse effects of GR signaling have also been reported to act directly 3 
on cancer cells, and indicate that corticosteroids may interfere with the therapeutic efficacy of anti- 4 
cancer therapy. These include AR-independent CRPC progression through GR signaling with 5 
corticosteroids driving resistance of second-generation AR-antagonists (34), and point mutations in 6 
the ligand domain of AR including L701H, L702H, H875Y and T877A variants that are activated by 7 
iatrogenic corticosteroids (35,36) and drive resistance to abiraterone(37). 8 
 9 
As concomitant corticosteroid treatment may drive resistance, cancer progression and adversely 10 
impact OS, more caution is now warranted when using supportive corticosteroids in high-NLR 11 
mCRPC. These data need validated in further prospective cohorts but could change daily 12 
management of CRPC in urological oncology practices. The strength of our study originates from the 13 
uniqueness of studying NLR in a completed randomized phase II trial of low-dose corticosteroids in 14 
CRPC. Critique may be given on the fact that the trial did not include a placebo arm, therefore all our 15 
findings of NLR need be taken with caution as all patients were treated with corticosteroids, and the 16 
effects of NLR as determinant of outcome required additional analysis in other datasets. It must be 17 
noted that the intermittent corticosteroid arm did not induce any PSA responses and if not 18 
terminated early, may have been used as a control arm. Given the array of life-prolonging 19 
therapeutic options in CRPC, such as the taxanes docetaxel and cabazitaxel, the oral hormonal 20 
agents abiraterone and enzalutamide, as well as radium-223 and sipuleucel-T, we recommend 21 
limited use of single-agent steroids as no survival advantage has been demonstrated. With regard to 22 
our findings, we advocate caution in the use of low-dose corticosteroids in patients with a high NLR, 23 
pending other prospective studies. 24 
 25 
In conclusion, in patients with a high BL and on-treatment NLR, no apparent benefit from low-dose 26 
corticosteroid is witnessed. A pro-inflammatory environment in high NLR tumours may explain these 27 
findings, wherein corticosteroid treatment tips the scales in favor of the adverse effects that include 28 
accumulation and trafficking of immunoregulatory cells such as MDSCs and Tregs, decreased 29 
functional antigen presenting cells and effector T-lymphocytes, resulting in a tolerogenic tumour 30 
microenvironment supporting tumour growth, treatment resistance and an adverse outcome.  31 
 32 
33 
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Figure 1  Assessment of Neutrophil to Lymphocyte Ratio (NLR) in the POD (Prednisolone or 1 
Dexamethasone) Trial. Box and Whisker Plot for NLR (A) and Neutroophils and Lymphocytes 2 
(B) at Baseline (BL) and After Initiation of Corticosteroid Treatment in the POD Trial. The 3 
Increase Observed in NLR and Neutrophils From BL to 6- and 12-Week Time Points and at 4 
End of Treatment (EOT) Was Statistically Significant. Also Paired Testing Revealed Significant 5 
Increases at Both Time Points (Both P<.001, Wilcoxon Paired Rank Test n [50 and n[48). 6 
Depicts Significance at the *P<.05; **P<.01; ***P<.001; and ****P<.0001 level 7 
 8 
 9 
 10 
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Figure 2. Time to Prostate-Specific Antigen (PSA) Progression (TTPSAPD) in Patients With 1 
Unfavorable Neutrophil to Lymphocyte Ratio (NLR; ‡2.6 or Median) and Favorable NLR (<2.6 2 
or Median). The Median TTPSAPD in Patients With Unfavorable or Favorable NLR at Baseline 3 
(A) Was 3.3 Months (95% CI, 2.8-4.2) and 6.1 Months (95% CI, 5.3-7.0), Respectively. The 4 
Median TTPSAPD in Patients With an Unfavorable or Favorable NLR in the Landmark 5 
Analysis at 6 Weeks (B) Was 2.7 Months (95% CI, 2.4-4.7) and 8.5 Months (95% CI, 5.2-14.8), 6 
Respectively. 7 
8 
 9 
 10 
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Figure 3  Overall Survival (OS) in Patients With Neutrophil to Lymphocyte Ratio (NLR) ‡ 2.6 1 
(Median) and NLR <2.6 (Median). The Median OS in Patients With High or Low NLR at 2 
Baseline Was 21.9 Months (95% CI, 19.3- 24.4) and 33.1 Months (95% CI, 24.2-42.0), 3 
Respectively. 4 
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Table 1 Univariate and Multivariate Cox Model of the Association Between 1 
Clinicopathological and Prognostic Factors and the Time to PSA Progression. 2 
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Supplementary Table 1. The NLR Values of Patients in the Combined Corticosteroid 1 
Treatment Arm and for Prednisolone and Dexamethasone 2 
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Supplementary Table 2. Univariate and Multivariate Cox Regression Analysis of the 1 
Association Between Clinicopathological and Prognostic Factors and Overall Survival 2 
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